Unnamed: 0,title,date,stock,sentiment
476102.0,Fate Therapeutics shares are trading. The company late Monday priced its 6.18 million share common stock offering at $28.31 per share.,2020-06-09 08:38:00-04:00,FATE,positive
476103.0,Fate Therapeutics Announces Proposed Public Offering of Common Stock; No Terms Disclosed,2020-06-08 16:02:00-04:00,FATE,negative
476104.0,"Fate Therapeutics Reports FDA Clearance For Investigational New Drug Application For FT538, CRISPR-Edited, iPSC-Derived Cell Therapy",2020-05-20 08:21:00-04:00,FATE,neutral
476105.0,"HC Wainwright & Co. Initiates Coverage On Fate Therapeutics with Buy Rating, Announces Price Target of $42",2020-05-13 07:30:00-04:00,FATE,neutral
476106.0,"BMO Capital Maintains Market Perform on Fate Therapeutics, Raises Price Target to $29",2020-05-12 10:24:00-04:00,FATE,neutral
476107.0,"Fate Therapeutics Q1 EPS $(0.440) Misses $(0.390) Estimate, Sales $2.515M Beat $1.800M Estimate",2020-05-11 16:17:00-04:00,FATE,negative
476108.0,"Oppenheimer Maintains Outperform on Fate Therapeutics, Lowers Price Target to $34",2020-04-06 10:57:00-04:00,FATE,negative
476109.0,"Wedbush Maintains Outperform on Fate Therapeutics, Raises Price Target to $41",2020-04-03 10:33:00-04:00,FATE,neutral
476110.0,Fate Therapeutics Announces Worldwide Collaboration With Janssen For Novel IPSC-derived Cell-Based Cancer Immunotherapies; Co. To Receive $50M Upfront And $50M Equity Investment And Eligible To Receive Up To $1.8B,2020-04-02 16:47:00-04:00,FATE,negative
476111.0,Fate Therapeutics Announces First Patient Treated In First-in-Human Clinical Trial Of FT596 And Provides Corporate Update,2020-04-02 16:45:00-04:00,FATE,neutral
476112.0,Fate Therapeutics shares are trading higher after Barclays and Citigroup issued bullish ratings on the stock.,2020-03-04 09:59:00-05:00,FATE,positive
476113.0,"Citigroup Maintains Buy on Fate Therapeutics, Raises Price Target to $41",2020-03-04 07:49:00-05:00,FATE,neutral
476114.0,"Barclays Initiates Coverage On Fate Therapeutics with Overweight Rating, Announces $40 Price Target",2020-03-04 05:22:00-05:00,FATE,negative
476115.0,"Oppenheimer Maintains Outperform on Fate Therapeutics, Raises Price Target to $36",2020-03-03 08:53:00-05:00,FATE,neutral
476116.0,Fate Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,2020-03-02 16:09:00-05:00,FATE,positive
476117.0,"Fate Therapeutics Q4 EPS $(0.37) Beats $(0.39) Estimate, Sales $2.802M Beat $1.8M Estimate",2020-03-02 16:02:00-05:00,FATE,neutral
476118.0,"Mizuho Maintains Buy on Fate Therapeutics, Raises Price Target to $40",2020-02-26 11:20:00-05:00,FATE,neutral
476119.0,"Wedbush Maintains Outperform on Fate Therapeutics, Raises Price Target to $33",2020-02-14 07:35:00-05:00,FATE,neutral
476120.0,Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood,2020-01-13 08:23:00-05:00,FATE,neutral
476121.0,"Mizuho Reiterates Buy on Fate Therapeutics, Raises Price Target to $33",2019-12-30 06:28:00-05:00,FATE,neutral
476122.0,"BMO Capital Maintains Outperform on Fate Therapeutics, Lowers Price Target to $22",2019-12-09 09:47:00-05:00,FATE,negative
476123.0,Fate Therapeutics shares are trading higher after the company announced positive preliminary data from its FT596 study and Wells Fargo upgraded its rating of the stock to Outperform.,2019-12-09 08:23:00-05:00,FATE,positive
476124.0,"Wells Fargo Upgrades Fate Therapeutics to Outperform, Announces $24 Price Target",2019-12-09 06:29:00-05:00,FATE,positive
476125.0,"SunTrust Robinson Humphrey Initiates Coverage On Fate Therapeutics with Buy Rating, Announces $25 Price Target",2019-11-12 06:25:00-05:00,FATE,neutral
476126.0,"BMO Capital Maintains Outperform on Fate Therapeutics, Lowers Price Target to $26",2019-11-06 09:53:00-05:00,FATE,negative
476127.0,"Wells Fargo Downgrades Fate Therapeutics to Market Perform, Lowers Price Target to $16",2019-11-06 06:14:00-05:00,FATE,positive
476128.0,"Fate Therapeutics Q3 EPS $(0.4) Misses $(0.38) Estimate, Sales $2.4M Beat $1.79M Estimate",2019-11-05 16:10:00-05:00,FATE,negative
476129.0,"UPDATE: Stifel Initiates Fate Therapeutics With Buy, $27 Target As Firm Notes 'We think the next clinical catalyst for FT500 and FT516 will be positive events for the stock'",2019-10-01 10:57:00-04:00,FATE,positive
476130.0,"Stifel Initiates Coverage On Fate Therapeutics with Buy Rating, Announces $27 Price Target",2019-10-01 07:03:00-04:00,FATE,neutral
476131.0,"Piper Jaffray Maintains Overweight on Fate Therapeutics, Lowers Price Target to $28",2019-09-16 07:04:00-04:00,FATE,negative
476132.0,Fate Therapeutics shares are trading lower after the company reported a common stock offering with no size disclosed.,2019-09-11 16:03:00-04:00,FATE,negative
476133.0,"Fate Therapeutics Reports Common Stock Offering, Size Not Disclosed",2019-09-11 16:01:00-04:00,FATE,neutral
476134.0,Fate Therapeutics Announces Issuance Of Foundational US Patent Covering iPSC-Derived CAR T Cells,2019-08-14 08:04:00-04:00,FATE,neutral
476135.0,"BTIG Initiates Coverage On Fate Therapeutics with Buy Rating, Announces $27 Price Target",2019-08-09 09:30:00-04:00,FATE,neutral
476136.0,"Fate Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate, Sales $2.817M Up From $1.027M YoY",2019-08-06 16:21:00-04:00,FATE,negative
476137.0,"UPDATE: Cantor Fitzgerald Initiates Fate Therapeutics With Overweight, $32 Tgt As Firm Thinks Co. 'is pioneering a highly scalable next-generation cell-therapy manufacturing process using induced pluripotent stem cells (iPSCs) that could be first class'",2019-07-22 11:25:00-04:00,FATE,negative
476138.0,"Cantor Fitzgerald Initiates Coverage On Fate Therapeutics with Overweight Rating, Announces $32 Price Target",2019-07-22 07:56:00-04:00,FATE,negative
476139.0,"Oppenheimer Initiates Coverage On Fate Therapeutics with Outperform Rating, Announces $27 Price Target",2019-07-12 06:35:00-04:00,FATE,neutral
476140.0,"Mizuho Initiates Coverage On Fate Therapeutics with Buy Rating, Announces $27 Price Target",2019-06-13 06:27:00-04:00,FATE,neutral
476141.0,"Roth Capital Initiates Coverage On Fate Therapeutics with Neutral Rating, Announces $20 Price Target",2019-06-07 06:57:00-04:00,FATE,neutral
476142.0,"Guggenheim Initiates Coverage On Fate Therapeutics with Buy Rating, Announces $25 Price Target",2019-05-31 07:24:00-04:00,FATE,neutral
476143.0,"Citi Assumes Fate Therapeutics, Inc. - Common Stock at Buy, Raises Price Target $26",2019-05-24 09:26:00-04:00,FATE,neutral
476144.0,Fate Therapeutics Announces FT500 Clinical Trial Now Open for Enrollment in Checkpoint Inhibitor Combination Arm for Treatment of Advanced Solid Tumors,2019-05-07 17:13:00-04:00,FATE,positive
476145.0,Fate Therapeutics Announces No Dose-Limiting Toxicities or Serious Adverse Events Reported in Initial Cohort of FT500 iPSC-derived NK Cell Cancer Immunotherapy Patients,2019-05-07 17:12:00-04:00,FATE,negative
476146.0,Fate Therapeutics Announces First-Ever Patient Treated In U.S. With An Ipsc-Derived Cell Therapy Successfully Advances Through Six-Dose Treatment Course,2019-05-07 17:12:00-04:00,FATE,positive
476147.0,"Fate Therapeutics Q1 EPS $(0.3) Misses $(0.24) Estimate, Sales $2.632M Beat $2.37M Estimate",2019-05-07 17:10:00-04:00,FATE,negative
476148.0,Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting,2019-04-24 08:01:00-04:00,FATE,neutral
476149.0,Fate Therapeutics Announces First Patient Treated With iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment,2019-04-02 08:07:00-04:00,FATE,positive
476150.0,Fate Therapeutics Highlights Presentation Of Late-Breaking Preclinical Data Highlighting Unique Advantages Of Clonal Master Engineered iPSC Lines For Off-The-Shelf CAR T-cell Therapy At 2019 AACR Annual Meeting,2019-04-01 08:02:00-04:00,FATE,positive
476151.0,"SVB Leerink Initiates Coverage On Fate Therapeutics with Outperform Rating, Announces $20 Price Target",2019-03-28 06:48:00-04:00,FATE,neutral
476152.0,"Fate Therapeutics Q4 EPS $(0.25) Misses $(0.24) Estimate, Sales $1.661M Miss $2.89M Estimate",2019-03-05 16:39:00-05:00,FATE,negative
476153.0,Fate Therapeutics Announces FDA Clearance Of IND Application For Cell Therapy Derived From Engineered Pluripotent Stem Cell,2019-02-06 08:01:00-05:00,FATE,neutral
476154.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:20:00-05:00,FATE,neutral
476155.0,Fate Therapeutics Secures Exclusive Option To Novel Humanized Anti-BCMA CAR Constructs For Development Of iPSC-derived Cell Products,2018-12-03 16:01:00-05:00,FATE,positive
476156.0,Fate Therapeutics shares are trading higher after the company announced receipt of FDA clearance  of an Investigational New Drug application for its FT500 cell cancer therapy.,2018-11-30 14:45:00-05:00,FATE,negative
476157.0,"Fate Therapeutics Announces FDA Clearance Of Landmark IND For FT500 iPSC-Derived, Off-the-Shelf NK Cell Cancer Immunotherapy",2018-11-30 08:00:00-05:00,FATE,negative
476158.0,"Jefferies Initiates Coverage On Fate Therapeutics with Buy Rating, Announces $17 Price Target",2018-11-05 09:16:00-05:00,FATE,neutral
476159.0,"Fate Therapeutics Q3 EPS $(0.31) Misses $(0.25) Estimate, Sales $1.026M Miss $2.87M Estimate",2018-11-01 16:38:00-04:00,FATE,negative
476160.0,Fate Therapeutics Announces Seven Presentations At The 2018 ASH Annual Meeting Dec 1-4,2018-11-01 09:08:00-04:00,FATE,neutral
476161.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,FATE,neutral
476162.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,FATE,neutral
476163.0,"Stocks Which Set New 52-Week High Yesterday, September 24th",2018-09-25 09:06:00-04:00,FATE,neutral
476164.0,"Stocks Which Set New 52-Week High Yesterday, September 20th",2018-09-21 08:16:00-04:00,FATE,neutral
476165.0,Fate Therapeutics Prices 9.2M Share Public Offering of Common Stock @$13.50/Share,2018-09-21 04:19:00-04:00,FATE,positive
476166.0,"Fate Therapeutics Reports Offering Of Common Shares, No Size Disclosed",2018-09-20 16:11:00-04:00,FATE,neutral
476167.0,"Fate Therapeutics Late Monday Announced Strategic Collaboration With ONO Pharmaceutical To Develop Off-The-Shelf, iPSC-Derived CAR-T Cell Cancer Immunotherapies",2018-09-18 08:21:00-04:00,FATE,negative
476168.0,"Fate Therapeutics Enters Into Exlusive License Agreement With Gladstone Institutes For CRISPR-Based Cellular Reprogramming, New Approach Uses CRISPR-Mediated Genome Activation For iPSC Generation",2018-09-13 08:02:00-04:00,FATE,positive
476169.0,"Fate Therapeutics Q2 EPS $(0.37) Misses $(0.31) Estimate, Sales $1.03M Miss $1.18M Estimate",2018-08-06 16:18:00-04:00,FATE,negative
476170.0,"Citigroup Initiates Coverage On Fate Therapeutics with Buy Rating, Announces $20 Price Target",2018-08-01 09:01:00-04:00,FATE,neutral
476171.0,"Fate Therapeutics Reports Expanded Scope Of Licensing Deal With Memorial Sloan Kettering Cancer Center To Include Gene-Edited T-Cell Immunotherapies, No Terms Disclosed",2018-05-16 08:11:00-04:00,FATE,negative
476172.0,"Fate Therapeutics Q1 EPS $(0.27) Misses $(0.22) Estimate, Sales $1.026M Miss $1.68M Estimate",2018-05-10 16:38:00-04:00,FATE,negative
476173.0,Fate Therapeutics S-3 Shows Registration For $150M Mixed Securities Shelf,2018-05-04 16:14:00-04:00,FATE,positive
476174.0,Fate Therapeutics Reports Initial Clinical Data Of FATE-NK100 For Recurrent Ovarian Cancer: 'Stable Disease with Tumor Shrinkage Reported in Subject 2 Following Single Dose of NK100',2018-03-29 08:02:00-04:00,FATE,negative
476175.0,Fate Therapeutics Shares Down 7.8% Following Q4 EPS Miss Reported Monday,2018-03-06 12:53:00-05:00,FATE,positive
476176.0,"BMO Capital Maintains Outperform on Fate Therapeutics, Raises Price Target to $20.00",2018-03-06 08:45:00-05:00,FATE,neutral
476177.0,"H.C. Wainwright Downgrades Fate Therapeutics to Neutral, Raises Target to $12.00",2018-03-06 08:04:00-05:00,FATE,neutral
476178.0,"Wedbush Maintains Outperform on Fate Therapeutics, Raises Price Target to $19.00",2018-03-06 07:40:00-05:00,FATE,neutral
476179.0,"Fate Therapeutics Reports Q4 EPS $(0.29) vs $(0.24) Est., Sales $1M vs $940K Est.",2018-03-05 16:02:00-05:00,FATE,neutral
476180.0,Fate Therapeutics Shares Down 7.9% On Potential Profit-Taking After Making New 52-Week High Tuesday,2018-01-24 14:55:00-05:00,FATE,positive
476181.0,"Fate Therapeutics Shares Make New 52-Week High Of $9.78, Now Up 9.65% On ~4x Avg. Volume At $9.09",2018-01-23 14:26:00-05:00,FATE,positive
476182.0,"Fate Therapeutics Shares Continuing Higher Fri., Up 12%; Stock Up Nearly 30% Over Last 3 Sessions; Amended 13G Filing From Redmile Tues. Afternoon Showed Raised Stake From ~1.4M Shares At End Of Last Qtr. To ~6.6M Shares, Or 12.6% Stake",2017-12-22 12:15:00-05:00,FATE,positive
476183.0,"PiperJaffray Initiates Coverage On Fate Therapeutics with Overweight Rating, Announces $10.00 Price Target",2017-12-18 09:14:00-05:00,FATE,negative
476184.0,Fate Therapeutics Prices 9.525M Share Offering at $4.20/Shre,2017-12-13 08:00:00-05:00,FATE,positive
476185.0,"Fate Therapeutics Announces Common Stock Offering, No Size Disclosed",2017-12-12 16:12:00-05:00,FATE,negative
476186.0,Watch Shares of Fate Therapeutics After the Company Earlier Gave an Update on its Phase 1 PROTECT Trial,2017-12-12 07:51:00-05:00,FATE,positive
476187.0,Fate Therapeutics Reports 1st Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer,2017-12-08 16:01:00-05:00,FATE,negative
476188.0,"Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 Shows No Dose Limiting Toxicities Reported,  Subject in Dose Cohort 2 Achieves Morphologic Leukemia-free State at Day 14",2017-11-10 08:01:00-05:00,FATE,negative
476189.0,"Fate Therapeutics Q3 EPS $(0.26) vs $(0.24) Est., Sales $1.03M vs $0.93M Est.",2017-11-01 16:41:00-04:00,FATE,neutral
476190.0,"H.C. Wainwright Assumes Fate Therapeutics at Buy, Announces price target $7.00",2017-10-12 07:04:00-04:00,FATE,neutral
476191.0,Fate Therapeutics Reports Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy,2017-08-16 08:05:00-04:00,FATE,neutral
476192.0,"Fate Therapeutics Reports Q2 EPS $(0.23) vs $(0.24) Est., Sales $1.026M vs $940K Est.",2017-08-14 16:04:00-04:00,FATE,neutral
476193.0,Fate Therapeutics Reports FDA Clearance Of Third IND For FATE-NK100,2017-08-08 12:00:00-04:00,FATE,neutral
476194.0,"Fate Therapeutics Reports Q1 EPS $(0.24) vs $(0.20) ESt., Sales $1.027M vs $950K Est.",2017-05-15 16:01:00-04:00,FATE,neutral
476195.0,Fate Therapeutics Reports FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors,2017-05-10 08:09:00-04:00,FATE,positive
476196.0,"Fate Therapeutics Reports Q4 EPS $(0.21) vs $(0.29) Est., Sales $1.027M vs $960K Est.",2017-03-16 16:02:00-04:00,FATE,neutral
476197.0,Fate Therapeutics Reports FDA Clearance of Investigational NDA for FATE-NK100 Immunotherapy,2017-03-13 08:02:00-04:00,FATE,neutral
476198.0,"Wedbush Reiterates Outperform On Fate Therapeutics, Maintains $7 Price Target",2017-02-28 06:31:00-05:00,FATE,neutral
476199.0,"Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma",2017-02-15 10:29:00-05:00,FATE,neutral
476200.0,Filing from Fate Therapeutics Shows Registration for ~20.86M Share Common Stock Offering via Selling Holders,2017-01-25 16:23:00-05:00,FATE,positive
476201.0,Roth Capital Initiates Coverage on Fate Therapeutics at Buy,2016-09-22 08:13:00-04:00,FATE,neutral
476202.0,H.C. Wainwright Assumes Fate Therapeutics at Buy,2016-07-28 09:40:00-04:00,FATE,neutral
476203.0,"BMO Capital Initiates Coverage on Fate Therapeutics at Outperform, Announces $4.00 PT",2016-04-12 06:01:00-04:00,FATE,neutral
476204.0,Wells Fargo Initiates Coverage on Fate Therapeutics at Outperform,2015-12-04 07:50:00-05:00,FATE,positive
476205.0,"Raymond James Initiates Coverage on Fate Therapeutics at Outperform, Announces $8.00 PT",2015-10-06 08:14:00-04:00,FATE,neutral
476206.0,"Leerink Swann Initiates Coverage on Fate Therapeutics at Outperform, Announces $10.00 PT",2015-06-01 06:24:00-04:00,FATE,neutral
476207.0,Fate Therapeutics Prices 6M Share Offering @$5.00/Share,2015-05-21 04:37:00-04:00,FATE,positive
476208.0,Fate Therapeutics Announces Positive Initial Data from Ongoing Phase 2 PUMA Study,2014-12-18 07:05:00-05:00,FATE,positive
476209.0,Fate Therapeutics Presents Positive Preclinical  Data  on Ex Vivo Programmed Hematopoietic Cells at ASH Annual Meeting,2014-12-06 12:32:00-05:00,FATE,positive
476210.0,Fate Therapeutics Reports Q2 EPS of $(0.30) vs $(0.36) Est,2014-08-12 16:08:00-04:00,FATE,neutral
476211.0,Fate Therapeutics Announces Up to $20M in Debt Financing ,2014-07-31 16:28:00-04:00,FATE,negative
476212.0,Fate Therapeutics Reports Q1 EPS of $(0.34) vs $(0.33) Est,2014-05-13 16:11:00-04:00,FATE,neutral
476213.0,Fate Therapeutics Reports Q4 EPS of $(0.29) vs $(0.27) Est,2014-03-17 16:02:00-04:00,FATE,neutral
476214.0,Fate Therapeutics Initiates Phase 2 Clinical Trial of PROHEMA for Treatment of Hematologic Malignancies ,2014-03-12 07:09:00-04:00,FATE,neutral
476215.0,Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment from Phase 1b Study of PROHEMA,2014-02-26 07:05:00-05:00,FATE,neutral
476216.0,Fate Therapeutics Reports Q3 EPS of $(4.81) Which May Not Compare $(0.32) Est; Revenue of $209.0K,2013-11-13 16:02:00-05:00,FATE,neutral
476217.0,UPDATE: Wedbush Initiates Coverage on Fate Therapeutics on Potential of Modified HSCs,2013-10-28 09:30:00-04:00,FATE,neutral
476218.0,Cowen Initiated Coverage on Fate Therapeutics with an Outperform Rating,2013-10-28 08:29:00-04:00,FATE,neutral
476219.0,"BMO Initiates Fate Therapeutics with Outperform Rating, $11 Price Target",2013-10-28 08:12:00-04:00,FATE,neutral
476220.0,Fate Therapeutics IPO Opens at $6.56 After Pricing at $6,2013-10-01 11:00:00-04:00,FATE,neutral
476221.0,"Quoting in IPO for Fate Therapeutics Now Open, Issue Expected to Begin Trade at 11AM EDT",2013-10-01 10:46:00-04:00,FATE,neutral
476222.0,Fate Therapeutics Prices IPO of 6.7M Shares at $6/Share,2013-10-01 08:47:00-04:00,FATE,positive
